Search PubMed⌕ Search

Biomedical subjects

R Mazzara

Publications and source records attributed to R Mazzara.

58 records · Page 4Linked to original sources

Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients.

The Baumgartner perfusion technique was used as an experimental model to study the combined influence of red cell (RBC) and platelet counts on the interaction of platelets with the subendothelium. At normal hematocrit and a platelet count of 100,000 per microliter, platelet adhesion and platelet aggregate (PAG) formation on subendothelium were statistically decreased. At lower platelet counts (50,000/microliter), there was an even more marked reduction in the formation of PAGs. The critical role of RBCs was demonstrated in experiments at low hematocrit; the formation of PAGs was impaired in perfusions at 20 percent hematocrit at any platelet count tested. Platelet deposition on subendothelium was almost absent at 50,000 platelets per microliter, suggesting a negative synergistic effect for the association of low hematocrit (20%) with a low platelet count. Perfusion experiments carried out with nonanticoagulated blood drawn directly from anemic patients with mild thrombocytopenia (43,000-58,000 platelets/microliter) before and after RBC transfusion were in agreement with previous experiments that indicated that normalization of both platelet count and hematocrit is required to achieve optimum hemostasis. Our data give experimental support for the transfusional management of patients with anemia and thrombocytopenia.

Anemia↗

Anti-K1 of the IgA class associated with Morganella morganii infection.

An anti-K1 alloantibody developed in a patient infected with Morganella morganii. The serologic behavior and response to dithiothreitol initially suggested that the alloantibody was an IgM. However, flow cytometry and the separation of immunoglobulin classes by serum chromatography revealed that the anti-K1 was constituted solely of IgA. These data suggest that bacteria-induced red cell antibodies might be of the IgA class.

Aged↗

Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: studies under flow conditions.

BACKGROUND: The possibility of developing synthetic platelet substitutes that could promote hemostasis with prolonged shelf-life and increased safety is an appealing one. STUDY DESIGN AND METHODS: Preparations containing synthetic phospholipids were incorporated into blood samples (1.15 mg/mL) in which platelets and white cell counts had been experimentally reduced by a filtration procedure. Vesicles containing phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), or combinations of PC and PE and of PC and PS were tested in this system. Blood was recirculated (10 min; shear rate, 250/sec) through a perfusion chamber containing vascular segments. The ability of the various phospholipid preparations to promote fibrin formation on the damaged subendothelium was evaluated morphometrically and expressed as the percentage of fibrin coverage. Generation of thrombin in the system was monitored through the measurement of prothrombin fragments 1 and 2. RESULTS: Vesicles containing PC, PI, PE:PC (1:1), or PS:PC (1:3) increased fibrin deposition on the subendothelium (64.5 +/- 9.8%, 32.7 +/- 6.3%, 58.3 +/- 6.5%, and 46.6 +/- 15.2%, respectively; p < 0.01 vs. 11.5 +/- 1.2% in thrombocytopenic blood). Vesicles containing PE, PS, or PS:PC (3:1) did not show procoagulant effect. CONCLUSION: Synthetic phospholipid preparations promote a local procoagulant activity at sites of vascular damage when they are incorporated into thrombocytopenic blood maintained under flow conditions.

Animals↗

Two-stage papain-indirect antiglobulin test and LISS direct agglutination are not appropriate for pretransfusion screening for unexpected antibodies.

BACKGROUND: The screening for unexpected antibodies has proved to be a suitable pretransfusion compatibility method, but controversy still remains regarding the most appropriate serologic techniques to use in such a screening and, in particular, whether or not to use enzyme-based methods. METHODS: Over a period of three years, 27,149 patient sera submitted to pretransfusion testing were screened for unexpected antibodies. Serologic techniques included LISS-direct agglutination (DAG) reading plus indirect antiglobulin test (IAT), and two-stage papain (2SP)-IAT. RESULTS: In all, 592 (2.18%) serum samples yielded a positive result. Further studies of these specimens disclosed 466 alloantibodies in 371 cases, and 221 unwanted positive reactivities. 2SP-IAT and LISS-DAG allowed the detection of 124 alloantibodies missed by LISS-IAT (78 anti-Lewis, 33 anti-E, 7 anti-P1, 2 anti-K1, 2 anti-K3, 1 anti-M, 1 anti-Cw), but were responsible for 81% of the unwanted positive reactivities. CONCLUSIONS: Since most alloantibodies detected only by 2SP-IAT or LISS-DAG were of doubtful clinical significance, and these techniques produced a high number of unwanted positive reactivities, we conclude that 2SP-IAT and LISS-DAG are not appropriate for the pretransfusion screening for unexpected antibodies.

Agglutination Tests↗